Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Gemcitabine and Carboplatin in Advanced Urothelial Carcinoma
NCT00588666Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2006
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Time to Disease Progression at 3 years. Started May 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00588666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00588666.